- Home
- TOP vs CTSO Comparison
TOP vs CTSO Comparison
Compare TOP & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOP
- CTSO
- Stock Information
- Founded
- TOP 2015
- CTSO 1997
- Country
- TOP Hong Kong
- CTSO United States
- Employees
- TOP N/A
- CTSO N/A
- Industry
- TOP Investment Bankers/Brokers/Service
- CTSO Medical/Dental Instruments
- Sector
- TOP Finance
- CTSO Health Care
- Exchange
- TOP Nasdaq
- CTSO Nasdaq
- Market Cap
- TOP 44.1M
- CTSO 68.2M
- IPO Year
- TOP 2022
- CTSO N/A
- Fundamental
- Price
- TOP $1.17
- CTSO $0.87
- Analyst Decision
- TOP
- CTSO Strong Buy
- Analyst Count
- TOP 0
- CTSO 3
- Target Price
- TOP N/A
- CTSO $4.67
- AVG Volume (30 Days)
- TOP 51.4K
- CTSO 138.7K
- Earning Date
- TOP 05-20-2025
- CTSO 05-14-2025
- Dividend Yield
- TOP N/A
- CTSO N/A
- EPS Growth
- TOP N/A
- CTSO N/A
- EPS
- TOP N/A
- CTSO N/A
- Revenue
- TOP $2,730,890.00
- CTSO $35,594,520.00
- Revenue This Year
- TOP N/A
- CTSO $18.72
- Revenue Next Year
- TOP N/A
- CTSO $19.75
- P/E Ratio
- TOP N/A
- CTSO N/A
- Revenue Growth
- TOP N/A
- CTSO 14.51
- 52 Week Low
- TOP $1.00
- CTSO $0.70
- 52 Week High
- TOP $3.30
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- TOP 49.57
- CTSO 33.89
- Support Level
- TOP $1.11
- CTSO $0.87
- Resistance Level
- TOP $1.19
- CTSO $1.16
- Average True Range (ATR)
- TOP 0.06
- CTSO 0.07
- MACD
- TOP 0.00
- CTSO -0.02
- Stochastic Oscillator
- TOP 46.67
- CTSO 0.00
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.